Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
CA 2359335 A1 · Owner: Polansky, Jon R. · Inventors: Chen, Pu; Chen, Hua; Polansky, Jon R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
In a preferred aspect of the invention the upstream sequences of the TIGR , protein encoding sequence can be used to diagnose a sensitivity to steroids and a risk for glaucoma or ocular hypertensive disorders. Methods kits, and , nucleic acids containing polymorphisms base substitutions, or base additions located within the upstream region and within protein-encoding regions of the TIGR gene are also provided. The upstream sequences disclosed including the , TIGR promoter regions and those regions possessing functional characteristics associated with or possessed by the TIGR gene 5' regulatory region can also , be used to generate cells, vectors transgenic animals, and nucleic acid , …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 11, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 11, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 11, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.